Ablation therapy for low-grade non-invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new ablation therapy (a treatment that destroys tumors without surgery) in people with low-grade, non-invasive bladder cancer that comes back. It aims to see if this therapy can help avoid repeated surgeries.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have low-grade (non-aggressive) papillary bladder tumors that are not growing into muscle.
- You have had at least one low-grade bladder tumor removed in the past, and this is not your first episode.
- Your disease is intermediate-risk: you have 1 or 2 features like more than 1 tumor (but less than 5), a tumor under 3 cm, or a recurrence within 1 year.
- You have an ECOG performance status of 0 to 2 (you are up and active, up to needing some help but still able to care for yourself).
- You have not had BCG treatment for bladder cancer, and no high-grade bladder cancer in the past 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
This study tests a new drug called UGN-501, given directly into the bladder through a catheter, for people whose bladder cancer (non-muscle invasive) has returned after previous treatments. It aims to find the right dose and see if it helps control the cancer.
This trial tests using chemotherapy directly into the bladder to treat low-grade bladder cancer that has come back, as an alternative to surgery. It may help people with small, low-grade tumors avoid the need for a more invasive procedure.
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
This study is testing whether a urine or blood test can help guide BCG treatment for high-risk bladder cancer that hasn't spread into the muscle. It is only for people over 65 who are new to BCG therapy.
Hear when a new Non-muscle Invasive Bladder Cancer (NMIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.